Medical Policy
Photocoagulation of Macular Drusen

Table of Contents
- Policy: Commercial
- Coding Information
- Information Pertaining to All Policies
- Policy: Medicare
- Description
- References
- Authorization Information
- Policy History

Policy Number: 607
BCBSA Reference Number: 9.03.11A

Related Policies
- Endothelial Keratoplasty, #180
- Epiretinal Radiation Therapy for Age-Related Macular Degeneration, #610
- Gas Permeable Scleral Contact Lens, #371
- Implantation of Intrastromal Corneal Ring Segments, #235
- Intravitreal Angiogenesis Inhibitors for Choroidal Vascular Conditions, #343
- Keratoprosthesis, #221
- Orthoptic Training for the Treatment of Vision or Learning Disabilities, #611
- Transpupillary Thermotherapy for Treatment of Choroidal Neovascularization, #600
- Photodynamic Therapy for Choroidal Neovascularization, #599
- Phototherapeutic Keratectomy, #597
- Surgical Vision Services, #241
- Vision Services, #675

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Destruction of macular drusen by photocoagulation and photocoagulation (feeder vessel technique) are NOT MEDICALLY NECESSARY.

Prior Authorization Information
Pre-service approval is required for all inpatient services for all products.
See below for situations where prior authorization may be required or may not be required for outpatient services.
Yes indicates that prior authorization is required.
No indicates that prior authorization is not required.

<table>
<thead>
<tr>
<th></th>
<th>Outpatient</th>
<th>Inpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>This is not a covered service.</td>
<td>This is not a covered service.</td>
</tr>
</tbody>
</table>
Commercial PPO and Indemnity

Medicare HMO Blue™

Medicare PPO Blue™

This is not a covered service. This is not a covered service. This is not a covered service.

### CPT Codes / HCPCS Codes / ICD-9 Codes

The following codes are included below for informational purposes. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

There is no specific CPT code for this procedure.

### Description

Photocoagulation describes the use of focused laser energy to treat disease. Laser photocoagulation of macular drusen has been evaluated as a method of slowing progression to advanced age-related macular degeneration (AMD).

Age-related macular degeneration (AMD) is a painless, insidious process. In its earliest stages, it is characterized by minimal visual impairment and the presence of large or “soft” drusen, i.e., subretinal accumulations of cellular debris adjacent to the basement membrane of the retinal pigment epithelium.

Large drusen appear as large, pale yellow or pale gray domed elevations and result in thickening of the space between the retinal pigment epithelium and its blood supply, the choriocapillaris. Clinical and epidemiologic studies have shown that the presence of large and/or numerous soft drusen is associated with an increased risk of the development of choroidal neovascularization (CNV) in eyes with AMD. For example, in patients with bilateral drusen, the 3-year risk of developing CNV is estimated to be 13%, rising to 18% for those older than age of 65 years. The emergence of CNV greatly increases the risk of subsequent irreversible loss of vision.

Two different kinds of low energy laser therapies, argon and infrared laser, have been investigated as techniques to eliminate drusen by photocoagulation in an effort to prevent the evolution to CNV, ultimately leading to improved preservation of vision. The lasers used are those that are widely used for standard photocoagulation of extrafoveal CNV. Therefore, the treatment of macular drusen represents an additional indication for an existing laser approved by the U.S. Food and Drug Administration (FDA).

### Summary

Evidence from multiple trials indicates that drusen ablation does not prevent visual loss, CNV, or AMD. Furthermore, the evidence from trials indicates that drusen ablation may be accompanied by harm. The literature indicates that photocoagulation of macular drusen procedure is not clinically appropriate; this approach is considered not medically necessary.

### Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/2014</td>
<td>Medical policy ICD10 remediation: Formatting, editing and coding updates. No changes to policy statements.</td>
</tr>
<tr>
<td>4/2010</td>
<td>Comparison review of the BCBSA National medical policy; not medically necessary; non-coverage clarified</td>
</tr>
<tr>
<td>8/2008</td>
<td>Comparison review of the BCBSA National medical policy; not medically necessary</td>
</tr>
<tr>
<td>8/2007</td>
<td>Comparison review of the BCBSA Medical policy; not medically necessary</td>
</tr>
</tbody>
</table>
Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:
- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

References